Microcap Ledger Tectonic Therapeutic, Inc. $TECX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Watertown, MA
- Fiscal year end
- December 31
- Shares outstanding
- 19,549,366 [10-Q 2026-08-06]
What the company doesAI summary of filing
Tectonic Therapeutic is a clinical-stage biotechnology company that discovers and develops therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs) using its proprietary GEODe platform technology. The company has two lead product candidates: TX45, an Fc-relaxin fusion molecule in Phase 2 development for pulmonary hypertension associated with heart failure, and TX2100, a VHH-Fc fusion antibody in Phase 1a development for hereditary hemorrhagic telangiectasia. The company is pre-revenue and relies on third-party contract manufacturers for production of its clinical candidates, with no established commercial organization as of the filing date. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$47.53M | −$39.86M | $227.07M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | — | −$74.15B | −$60.08M | $253.80M | [DEF 14A 2026-04-24] |
| FY ended Dec 2024 | — | −$57.98B | −$59.08M | $141.24M | [DEF 14A 2026-04-24] |
- Quarterly cash burn
- −$19.93M
- Cash runway Estimate
- ~34.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 14,752,689 | [10-Q 2024-11-12] |
| 2025-03-01 | 18,662,672 | [10-K 2025-03-20] |
| 2025-05-01 | 18,672,509 | [10-Q 2025-05-08] |
| 2025-08-01 | 18,712,128 | [10-Q 2025-08-07] |
| 2025-11-03 | 18,716,280 | [10-Q 2025-11-06] |
| 2026-02-16 | 18,776,626 | [10-K 2026-02-26] |
| 2026-05-01 | 18,869,186 | [10-Q 2026-05-07] |
| 2026-07-31 | 19,549,366 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-07-07; declared effective 2025-07-15 [S-3 2025-07-07]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-30 | Mcnamara Peter | sell | 536 | $23.04 | [4 2026-10-02] |
| 2026-09-25 | Lochner Daniel | other | 520 | $23.67 | [4 2026-10-02] |
| 2026-09-25 | Mcnamara Peter | other | 444 | $23.67 | [4 2026-10-02] |
| 2026-09-25 | Ruddy Marcella K. | other | 525 | $23.67 | [4 2026-10-02] |
| 2026-09-25 | Reicin Alise | other | 1,545 | $23.67 | [4 2026-10-02] |
| 2026-09-25 | Schwabish Marc | other | 411 | $23.67 | [4 2026-10-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Other events |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-06-10 | 8-K | Shareholder vote results; Other events |
| 2026-05-07 | 8-K | Results of operations |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-04-24 | DEF 14A | Proxy statement |
| 2026-04-23 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-02-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-02-26 | 8-K | Results of operations |
| 2026-02-26 | 10-K | Annual report |
| 2026-02-24 | 8-K | Director or officer change; Regulation FD disclosure |
Alerts for $TECX
Email me when Tectonic Therapeutic, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.